3U2 Stock Chart & Stats
€0.86
-€0.03(-2.94%)
At close: 4:00 PM EDT
€0.86
-€0.03(-2.94%)
Day’s Range― - ―
52-Week Range€0.66 - €1.11
Previous CloseN/A
Volume0.00
Average Volume (3M)116.00
Market Cap
€773.71M
Enterprise Value€885.85M
Total Cash (Recent Filing)€180.30M
Total Debt (Recent Filing)€393.50M
Price to Earnings (P/E)26.2
Beta0.84
Next Earnings
Nov 19, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding968,011,200
10 Day Avg. Volume40
30 Day Avg. Volume116
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.68
Price to Sales (P/S)0.79
P/FCF Ratio5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.87Price Target Upside1.43% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€9.18M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSolid free cash flow and close alignment with operating cash flow indicate that reported earnings are converting into usable funds. This supports investment in the brand, debt reduction, and shareholder returns while providing resilience through a period of weaker revenue growth.
Improving LeverageThe sustained reduction in leverage improves financial flexibility and lowers balance-sheet pressure relative to earlier years. Although the capital structure is not conservative, continued debt reduction can strengthen resilience and leave more capacity for investment as trading conditions stabilize.
Operating Profit RecoveryThe rebound in operating margin shows that profitability can recover even before revenue growth fully returns. If maintained, better operating efficiency would improve earnings quality, support cash generation, and help restore the brand’s ability to fund growth from internal resources.
Bears Say
Multi-year Revenue DeclineRepeated annual revenue contraction signals weaker top-line momentum rather than a single temporary setback. Persistent declines can reduce operating leverage, limit reinvestment capacity, and make it harder for the company to rebuild earnings without renewed demand or stronger channel performance.
Profitability Remains Below Prior PeaksDespite the recent improvement, net profitability remains substantially below earlier levels. The reduced earnings buffer leaves less room to absorb weaker sales or cost pressure and means that revenue stabilization has not yet translated into a durable return to historical profit performance.
Gross Margin CompressionA materially lower gross margin reduces the profit retained from each sale and can constrain earnings even if revenue stabilizes. The decline also makes sustained recovery dependent on restoring product economics, pricing power, or channel mix rather than relying solely on volume growth.
Dr. Martens Plc News
3U2 FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest stock price was €0.66 and its highest was €1.11 in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is €773.71M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is Nov 19, 2026 which is in 69 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on May 19, 2026. The company reported €0.049 earnings per share for the quarter, missing the consensus estimate of €0.051 by -€0.002.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc does not currently pay dividends.
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is <0.01.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 968,011,200 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of €0.049 in its last earnings report, missing expectations of €0.051. Following the earnings report the stock price went up 3.659%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in DE:3U2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€0.87 (1.43% Upside)
€0.87 (1.43% Upside)
Insider Transactions
Bought Shares
Worth €100.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
3.77%
Trailing 12-Months
Asset Growth
-1.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dr. Martens Plc
Dr. Martens plc is a global footwear enterprise that handles the entire process of conceiving, crafting, sourcing materials for, marketing, selling, and distributing its products. The company boasts a significant international presence, serving customers across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region. Its extensive product range includes classic 'Originals' footwear, contemporary 'fusion' styles, children's shoes, and casual designs, alongside various accessories. All merchandise is offered exclusively under the renowned Dr. Martens brand. Established in 1945, Dr. Martens plc maintains its corporate headquarters in London, United Kingdom.
3U2 Stock 12 Month Forecast
Average Price Target
€0.87
▲(1.43% Upside)